Schizophrenia News

Teva Pharmaceuticals recently announced that the FDA approved Austedo tablets for the treatment of tardive dyskinesia in adults.

Obesity was significantly more common among individuals with schizophrenia or bipolar disorder, according to recent findings.

Functioning scores decreased among individuals who received inpatient treatment for psychosis 20 years after discharge, particularly among those with schizophrenia or schizoaffective disorder.

Clozapine use in treatment-resistant schizophrenia was associated with lower all-cause mortality and self-harm rates, according to recent findings.

MIN-101, a 5-HT2a and sigma2 antagonist from Minerva Neurosciences, significantly reduced negative symptoms in schizophrenia and was well-tolerated, according to recent findings.

Recent findings indicated impaired insulin/glucose homeostasis in drug-naïve individuals with first-episode schizophrenia.

Violent ideation and behavior were significant predictors of subsequent violent behavior and psychosis diagnosis among individuals at high risk for psychosis, according to recent findings.

ALKS 3831 — a single bilayer tablet of samidorphan co-formulated with olanzapine — appeared safe and effective for acute exacerbation of schizophrenia, according to phase 3 study results.

Recent findings indicated placebo effects in schizophrenia cognition trials were not large enough to impact a treatment effect with small or medium effect size.

Some antipsychotic and psychotropic drug combinations were effective for schizophrenia in adults, according to meta-analyses; however, there was high risk for bias in study content.